The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis

Published:2013-03-11 Issue:4 Volume:161 Page:508-516
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Verstovsek Srdan¹,Mesa Ruben A.²,Gotlib Jason³,Levy Richard S.⁴,Gupta Vikas⁵,DiPersio John F.⁶,Catalano John V.⁷,Deininger Michael⁸,Miller Carole⁹,Silver Richard T.¹⁰,Talpaz Moshe¹¹,Winton Elliott F.¹²,Harvey Jimmie H.¹³,Arcasoy Murat O.¹⁴,Hexner Elizabeth¹⁵,Lyons Roger M.¹⁶,Paquette Ronald¹⁷,Raza Azra¹⁸,Vaddi Kris⁴,Erickson-Viitanen Susan⁴,Sun William⁴,Sandor Victor⁴,Kantarjian Hagop M.¹

Affiliation:

1. The University of Texas MD Anderson Cancer Center; Houston TX USA

2. Mayo Clinic; Scottsdale AZ USA

3. Stanford Cancer Institute; Stanford CA USA

4. Incyte Corporation; Wilmington DE USA

5. Princess Margaret Hospital; University of Toronto; Toronto ON Canada

6. Washington University School of Medicine; St. Louis MO USA

7. Frankston Hospital; Frankston Australia

8. Oregon Health and Science University; Portland OR USA

9. Saint Agnes Cancer Institute; Baltimore MD USA

10. Weill Cornell Medical College; New York NY USA

11. University of Michigan; Ann Arbor MI USA

12. Emory University School of Medicine; Atlanta GA USA

13. Birmingham Hematology & Oncology; Birmingham AL USA

14. Duke Cancer Institute and Duke University Health System; Durham NC USA

15. Abramson Cancer Center at The University of Pennsylvania; Philadelphia PA USA

16. Cancer Care Centers of South Texas/US Oncology; San Antonio TX USA

17. UCLA Medical Hematology & Oncology; Los Angeles CA USA

18. Columbia Presbyterian Medical Center; New York NY USA

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.12274/fullpdf

Reference20 articles.

1. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet;Barbui;Journal of Clinical Oncology,2011

2. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment;Barosi;Leukemia,2008

3. Identification of ‘short-lived’ and ‘long-lived’ patients at presentation of idiopathic myelofibrosis;Cervantes;British Journal of Haematology,1997

4. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment;Cervantes;Blood,2009

5. Forest plots and the interpretation of subgroups;Cuzick;Lancet,2005

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story;Annals of the Rheumatic Diseases;2023-11-03

2. The role of therapy in the outcome of patients with myelofibrosis;Cancer;2023-05-27

3. Protein kinases: drug targets for immunological disorders;Nature Reviews Immunology;2023-05-15

4. Telocinobufagin inhibits osteosarcoma growth and metastasis by inhibiting the JAK2/STAT3 signaling pathway;European Journal of Pharmacology;2023-03

5. Relevant Clinical Factors in Patients with Myelofibrosis on Ruxolitinib for 5 or More Years;Acta Haematologica;2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3